EyePoint Pharmaceuticals (EYPT) Short Interest Ratio & Short Volume → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free EYPT Stock Alerts $11.76 -0.11 (-0.93%) (As of 03:04 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media EyePoint Pharmaceuticals Short Interest DataCurrent Short Volume6,540,000 sharesPrevious Short Volume6,850,000 sharesChange Vs. Previous Month-4.53%Dollar Volume Sold Short$139.17 millionShort Interest Ratio / Days to Cover6.7Last Record DateApril 15, 2024Outstanding Shares52,084,000 sharesPercentage of Shares Shorted12.56%Today's Trading Volume915,086 sharesAverage Trading Volume1,119,983 sharesToday's Volume Vs. Average82% Short Selling EyePoint Pharmaceuticals ? Sign up to receive the latest short interest report for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatEYPT Short Interest Over TimeEYPT Days to Cover Over TimeEYPT Percentage of Float Shorted Over Time Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide EyePoint Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20246,540,000 shares $139.17 million -4.5%N/A6.7 $21.28 3/31/20246,850,000 shares $141.59 million +4.1%N/A7.1 $20.67 3/15/20246,580,000 shares $141.34 million +15.0%N/A6.4 $21.48 2/29/20245,720,000 shares $155.64 million +20.4%N/A4.5 $27.21 2/15/20244,750,000 shares $138.13 million -7.6%N/A2.9 $29.08 1/31/20245,140,000 shares $138.42 million -1.2%N/A3.3 $26.93 Get the Latest News and Ratings for EYPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20245,200,000 shares $118.35 million -2.4%N/A3.5 $22.76 12/31/20235,330,000 shares $123.18 million +12.2%N/A3.9 $23.11 12/15/20234,750,000 shares $92.86 million -32.2%N/A3.6 $19.55 11/30/20237,010,000 shares $43.81 million +28.9%25.0%5.9 $6.25 11/15/20235,440,000 shares $36.39 million +1.7%19.4%10.3 $6.69 10/31/20235,350,000 shares $32.21 million +9.0%19.2%10.3 $6.02 10/15/20234,910,000 shares $39.77 million -29.3%17.6%9.3 $8.10 9/30/20236,940,000 shares $55.45 million +12.3%25.1%11.6 $7.99 9/15/20236,180,000 shares $64.77 million +9.2%22.3%10.2 $10.48 8/31/20235,660,000 shares $56.09 million +12.1%20.6%9.5 $9.91 8/15/20235,050,000 shares $71.66 million +3.7%18.8%8.9 $14.19 7/31/20234,870,000 shares $60.88 million +1.9%N/A9.3 $12.50 7/15/20234,780,000 shares $52.44 million -7.7%N/A4.9 $10.97 6/30/20235,180,000 shares $45.07 million +7.5%N/A5.6 $8.70 6/15/20234,820,000 shares $32.73 million +13.2%18.4%5.3 $6.79 5/31/20234,260,000 shares $25.77 million +5.2%16.2%4.8 $6.05 5/15/20234,050,000 shares $24.30 million +11.3%15.4%4.7 $6.00 4/30/20233,640,000 shares $22.86 million -0.3%14.1%4.4 $6.28 4/15/20233,650,000 shares $15.80 million +9.3%14.2%5.3 $4.33 3/31/20233,340,000 shares $9.82 million +19.7%13.0%11 $2.94 3/15/20232,790,000 shares $6.67 million +34.8%10.9%10 $2.39 2/28/20232,070,000 shares $6.91 million No Change8.1%8.1 $3.34 2/15/20232,070,000 shares $7.66 million -4.2%8.1%8.5 $3.70 1/31/20232,160,000 shares $10.07 million +6.9%8.6%9.3 $4.66 1/15/20232,020,000 shares $10.18 million +13.5%8.0%9.4 $5.04 12/30/20221,780,000 shares $6.23 million +6.0%7.1%12.3 $3.50 12/15/20221,680,000 shares $4.50 million -2.9%6.7%11.6 $2.68 11/30/20221,730,000 shares $5.54 million -3.4%6.9%13.6 $3.20 11/15/20221,790,000 shares $7.91 million -9.1%7.1%14.1 $4.42 10/31/20221,970,000 shares $10.64 million -1.5%N/A16.1 $5.40 10/15/20222,000,000 shares $11.20 million -1.5%7.7%14.3 $5.60 9/30/20222,030,000 shares $16.06 million -0.5%7.8%12.5 $7.91 9/15/20222,040,000 shares $16.30 million +0.5%7.9%12.7 $7.99 8/31/20222,030,000 shares $20.30 million +1.5%7.8%12.7 $10.00“Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. EYPT Short Interest - Frequently Asked Questions What is EyePoint Pharmaceuticals' current short interest? Short interest is the volume of EyePoint Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 6,540,000 shares of EYPT short. Learn More on EyePoint Pharmaceuticals' current short interest. What is a good short interest ratio for EyePoint Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EYPT shares currently have a short interest ratio of 7.0. Learn More on EyePoint Pharmaceuticals's short interest ratio. Which institutional investors are shorting EyePoint Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of EyePoint Pharmaceuticals: Perceptive Advisors LLC, and Affinity Asset Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is EyePoint Pharmaceuticals' short interest increasing or decreasing? EyePoint Pharmaceuticals saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 6,540,000 shares, a decline of 4.5% from the previous total of 6,850,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does EyePoint Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to EyePoint Pharmaceuticals: Quanterix Co. (3.21%), Standard BioTools Inc. (3.05%), Pacific Biosciences of California, Inc. (17.82%), Cytek Biosciences, Inc. (6.29%), Nautilus Biotechnology, Inc. (1.95%), Akoya Biosciences, Inc. (4.74%), Mesa Laboratories, Inc. (2.89%), Calliditas Therapeutics AB (publ) (0.02%), Stoke Therapeutics, Inc. (10.61%), The Pennant Group, Inc. (1.28%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short EyePoint Pharmaceuticals stock? Short selling EYPT is an investing strategy that aims to generate trading profit from EyePoint Pharmaceuticals as its price is falling. EYPT shares are trading down $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against EyePoint Pharmaceuticals? A short squeeze for EyePoint Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EYPT, which in turn drives the price of the stock up even further. How often is EyePoint Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EYPT, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Quanterix Short Interest Standard BioTools Short Interest Pacific Biosciences of California Short Interest Cytek Biosciences Short Interest Nautilus Biotechnology Short Interest Akoya Biosciences Short Interest Mesa Laboratories Short Interest Calliditas Therapeutics AB (publ) Short Interest Stoke Therapeutics Short Interest The Pennant Group Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EYPT) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsThe AI Stock that’s Disrupting Every IndustryStockEarnings